Navigation Links
Data Presented on Cempra Pharmaceutical's CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
Date:10/28/2009

CHAPEL HILL, N.C., Oct. 29 /PRNewswire/ -- Cempra Pharmaceuticals today announced a presentation on its novel fluoroketolide antibiotic, CEM-101, at the Infectious Diseases Society of America, 47th Annual Meeting, October 29 to November 1, 2009, in Philadelphia.

Susceptibility of CEM-101 and more than 25 other antibiotics was tested against 1,737 multidrug-resistant S. pneumoniae strains collected in 2008 from medical centers in the U.S., Europe and Latin America. CEM-101 demonstrated 100% coverage (100% inhibition at less than or equal to 1 microgram/ml) against these strains. Activity was slightly better than telithromycin (MIC90 of 0.25 microgram/ml for both; range of less than or equal to 0.008 to 1 for CEM-101 vs. less than or equal to 0.06 to 2 for telithromycin) and at least four-fold better than linezolid (MIC90 of 1 microgram/ml) or vancomycin (MIC90 of less than or equal to 1 microgram/ml). The study will be presented during a poster session on October 30.

CEM-101 is a new fluoroketolide antibiotic with potent and broad-spectrum activity against gram-positive and gram-negative pathogens, including multidrug-resistant strains, as well as non-bacterial pathogens such as Plasmodium falciparum. The compound recently completed a Phase 1 clinical trial and is in preparation for a Phase 2 trial in moderate to moderately-severe community-acquired bacterial pneumonia.

"The rise of multidrug-resistant organisms has become an increasing public health issue, particularly for vulnerable patient populations including those with challenging respiratory infections," said Prabhavathi Fernandes, Ph.D., Chief Executive Officer of Cempra Pharmaceuticals. "New medications are needed that are safe and effective against these difficult-to-treat pathogens. We believe that the growing database showing the potency and broad-spectrum activity of CEM-101, not only against the pneumococcal strains presented here, but agai
'/>"/>

SOURCE Cempra Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego
2. Medical Food Reduces Medical Costs and Use of Anticonvulsant Medication When Treating Diabetic Neuropathy, According to HealthCore Study Presented at ISPOR
3. Data from Jazz Pharmaceuticals First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia to be Presented at Upcoming Conferences
4. The Most Advanced Solution for the Reduction of Stretch Marks Based on TriPollar(R) Technology Presented at the Upcoming EADV Congress
5. Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects
6. OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting
7. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
8. ClariVein(TM) Catheter for Varicose Veins: Further Clinical Trial Results to Be Presented
9. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
10. New Micro-Bland Embolization Technique with Embozene(TM) Microspheres to Be Presented at the International Medical Conference in Lisbon, Portugal
11. QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... , NEWPORT BEACH, Calif., July ... from a clinical study showing patient-specific cancer vaccines derived from ... and resulted in impressive long-term survival rates in patients with ... , , The study entitled ...
... , PHILADELPHIA, July 28 Shire ... biopharmaceutical company, announces,that it has received a Complete Response letter ... Administration (FDA).,This decision comes following labeling discussions with the FDA ... PDUFA date. , The FDA did ...
Cached Medicine Technology:Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy 2Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy 3FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents 2FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents 3FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents 4FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents 5FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents 6
(Date:7/9/2014)... Researchers have found that fecal transplantation is effective ... immunocompromised patients. This is the result of a study ... Center for Women,s Gastrointestinal Medicine at The Women,s Medicine ... online in advance of print in the American ... or C. diff , has increased to epidemic ...
(Date:7/9/2014)... are personal and subjective, the human brain turns ... emotions across different senses, situations and even people, ... Adam Anderson. , "We discovered that fine-grained patterns ... area of the brain associated with emotional processing, ... individual,s subjective feeling," says Anderson, associate professor of ...
(Date:7/9/2014)... 8, 2014) Researchers from Montefiore Medical Center ... of Yeshiva University will present new findings at ... 12 July 17 in Copenhagen, Denmark. Data from ... prompt transition from cognitive normality to mild cognitive impairment ... Einstein Aging Study , established in 1980 to examine ...
(Date:7/9/2014)... smell of flatulence and have a reputation for being highly ... sulfide is now being being found to offer potential health ... heart attacks and dementia. A new compound (AP39), designed and ... to future therapies, by targeting delivery of very small amounts ... cells. , Scientists in Exeter have already found that ...
(Date:7/9/2014)... conducted by researchers at Tufts University School of Dental ... and developmental disabilities, the likelihood of having cavities decreased ... The findings, published in the July/August issue of ... designed to address the oral health of individuals in ... records of 107 patients at one of the eight ...
Breaking Medicine News(10 mins):Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Study cracks how the brain processes emotions 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3
... , , , WASHINGTON, ... Produce Safety Project: , , We commend the FDA ... The proposed guidance documents put out for comment today address three ... these documents quickly. We also look forward to the agency,s next ...
... ... in Webinar Series on "How Generation and Gender Impact Physician Engagement" , ... Charlotte, N.C. (Vocus) July 31, 2009 -- ... in Physician Engagement." The free hour-long ,webinar will be broadcast on Wednesday, August ...
... SHENZHEN, China, July 31 /PRNewswire-FirstCall/ ... announced today that its,registration dossier for MEVAC-DTaP (Diphtheria, Tetanus ... consideration,of the experts in Thai FDA. The sample analysis ... , Mr. Terry Yuan CEO ...
... , COLUMBIA, S.C., July 31 Amid rising ... benefits of including international medical travel coverage in their employee ... possible risks associated with offering such options. , , ... Global Healthcare Inc. today announced an agreement with an insurer ...
... skills, researchers say , FRIDAY, July 31 (HealthDay News) ... should learn cardiopulmonary resuscitation (CPR), Austrian researchers say. , In ... life-support training, 86 percent of the children performed CPR correctly ... to the report published online in the journal Critical ...
... , , , ... Language Line Services , the leading provider of ... evening, July 23rd at a Recognition and Awards Banquet at Bellevue University, ... Wray, President of the Nebraska Association for Translators & Interpreters (NATI), said, ...
Cached Medicine News:Health News:Webinar on "Physician Engagement - Diagnosing Generational Differences" Presented by Morehead Associates 2Health News:Webinar on "Physician Engagement - Diagnosing Generational Differences" Presented by Morehead Associates 3Health News:Hard to Treat Diseases, Inc. (HTDS) Thai Registration Dossier 2Health News:Hard to Treat Diseases, Inc. (HTDS) Thai Registration Dossier 3Health News:New Policies Protect Employers, Workers Who Choose Global Health Care 2Health News:Even 9-Year-Olds Can Learn CPR 2Health News:Language Line Services Honored by Nebraska Association for Translators & Interpreters (NATI) 2Health News:Language Line Services Honored by Nebraska Association for Translators & Interpreters (NATI) 3
When You Need Optimal Patient Comfort with Minimal Weight at a Nonunion Site...Demand The OrthoPak Noninvasive Bone Growth Stimulator., ,Most Appropriate for the Proximal Femur, Metatarsal/Tarsal...
... Providing the surgical versatility you demand when ... new EBI OsteoGen-D offers 40 microamperes of ... each with 20 microamperes. Available in both ... superior flexibility with any of your bone ...
... cataract surgery following refractive surgery grows larger ... for surgeons, as calculating IOL power for ... power following RK, ALK, PRK and LASIK ... or topography. For example, keratometry and simulated ...
... to offer one of the ... at only 188 grams! The ... superior flow rate with effortless ... The complementing electrodes provide powerful ...
Medicine Products: